ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Clinicopathological characteristics of RET rearranged lung cancer in European patients

Developments in oncological positron emission tomography/computed tomography assessment

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Comprehensive genomic profiles of small cell lung cancer.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

PD-L1 expression in small cell neuroendocrine carcinomas.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

CD74-NRG1 Fusions in Lung Adenocarcinoma

Ceritinib in ALK-rearranged non-small-cell lung cancer

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

A Genomics-Based Classification of Human Lung Tumors

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small.cell lung cancer

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Tumor VEGFR:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Molecular pathology of the lungs. New perspectives by next generation sequencing

Lung Cancer: Molecular pathology and personalized therapy

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

Genetic insight and therapeutic targets in squamous-cell lung cancer

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

Indications and limitations of fresh frozen sections in the pulmonary apparatus

Comprehensive genomic characterization of squamous cell lung cancers

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Early palliative care for patients with metastatic cancer

Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

Recommending early integration of palliative care – does it work?

Personalized therapy of lung cancer

The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET

A crucial requirement for Hedgehog signaling in small cell lung cancer

Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines

Blood-based gene expression signatures for early detection of lung cancer

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

Molecular diagnostics of lung cancer for treatment stratification

Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Cytohesins Are Cytoplasmic ErbB Receptor Activators

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium

Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors

Identification of lung cancer with high sensitivity and specificity by blood testing

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling